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Summary:  
This study demonstrates that children aged 15 years shed a 1.04- to 1.24-fold higher total 
quantity of influenza virus compared with older children associated with  an increased risk of 
acquiring resistance mutations following antiviral treatment. 
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Abstract  
Background  
The effect of age, baseline viral load, vaccination status, antiviral therapy and emergence of 
drug resistance on viral shedding in children infected with influenza A or B virus was studied. 
Methods  
Samples from children (aged ≤13 years) enrolled during the 7 years of the prospective 
Influenza Resistance Information Study (IRIS; NCT00884117) were analyzed by polymerase 
chain reaction to determine the influenza virus(sub-)type, viral load and resistance mutations. 
Disease severity was assessed; clinical symptoms were recorded. The association of age 
with viral load and viral clearance was examined by determining the area under the curve for 
viral RNA shedding using logistic regression and Kaplan-Meier analyses.   
Results  
A total of 2131 children infected with influenza (683 A/H1N1pdm09; 825 A/H3N2; 623 
influenza B) were investigated. Age did not affect the mean baseline viral load. Children aged 
15 years, infected with A/H1N1pdm09, A/H3N2 or influenza B virus had prolonged viral 
RNA shedding (1-2 days) compared with older children (aged >5 years) and up to 1.2-fold 
higher total viral burden. Besides older age (odds ratio [OR] 1.08; confidence interval [CI]: 
1.05-1.12), prior vaccination status (OR 1.72; CI: 1.22-2.43) and antiviral treatment (OR 1.74; 
CI: 1.43-2.12) increased the rate of viral clearance. Resistance mutations were detected in 
49 children infected with influenza A virus (34 A/H1N1pdm09; 15 A/H3N2) treated with 
oseltamivir, most of whom were aged <5 years (n = 39). 
Conclusions 
Children aged 15 years had a higher total viral burden with prolonged virus shedding and 
had an increased risk of acquiring resistance mutations following antiviral treatment.  
Key words:   
Influenza, pediatrics, Influenza Resistance Information Study, viral load, resistance mutations 
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Introduction   
Children are more likely to be infected with influenza virus during epidemics than adults [1]. 
Annually, pediatric infections are associated with a high number of emergency room visits 
and hospitalizations [2–5]. This susceptibility of children to influenza virus infection largely 
results from the absence of pre-existing acquired immunity [6,7]. Thus, children can serve as 
a major reservoir for further prolongation of outbreaks in the community [8–10]. Although 
several studies report prolonged influenza virus replication in children compared with adults, 
this finding is not consistently reported and remains to be elucidated [1,8–14]. 
 To gain further insight into the drivers of pediatric viral replication and antiviral 
resistance, studies with sufficient numbers of patients are needed to compare kinetics 
between the different age strata. The Influenza Resistance Information Study (IRIS) provided 
a unique opportunity to capitalize on the knowledge of influenza viral kinetics and the 
incidence of antiviral resistance in children [15–17]. With more than 2000 children included, it 
was possible to analyze the effect of age, baseline viral load, antiviral usage, emergence of 
resistance, and vaccination status of children on viral shedding and clearance for influenza A 
(A/H1N1pdm09, A/H3N2) and influenza B viruses.  
 
Methods 
Study design 
IRIS (NCT00884117) was a prospective, multicenter, non-randomized study undertaken from 
2008 to 2015. Study participants were enrolled from Europe, United States, China (Hong 
Kong), Australia and South Africa. The study was implemented in compliance with the 
principles of the Declaration of Helsinki and its amendments, and in accordance with Good 
Clinical Practice. Written informed consent was obtained from all study participants and/or 
their legal guardians. Local ethics committees and institutional review boards approved the 
study protocol and amendments.  
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Inclusion criteria and clinical assessment  
A detailed description of the study procedures has been previously published [15,17]. In 
brief, during the first 5 years of IRIS (December 2008 to March 2013), both adults and 
children aged ≥1 year were eligible for enrollment when positive for influenza virus by rapid 
test and/or upon display of influenza-like signs and symptoms within 48 hours (≤96 hours for 
hospitalized adults, no time limit for hospitalized children) [15]. Since resistance mutations 
were more prevalent in children during the first 5 years of the study, the inclusion criteria for 
the last 2 years of the study (March 2013 to September 2015) were modified to recruit only 
children aged 13 years on antiviral treatment. Clinical management, including prescription 
of antivirals was at the discretion of the healthcare provider.  
 For clinical assessment, patients were evaluated on days 1 (study enrollment), 6 and 
10. Influenza signs and symptoms were assessed by investigators at each center using a 4-
point scale [15]. Temperature (oral or tympanic) and adverse events (AE) were recorded 
daily on diary cards. In the last 2 years of the study, baseline and follow-up symptom 
assessments were conducted by the study physicians, but diary cards were not obtained.  
 
Virological assessment  
Qualitative, quantitative, and mutation specific real-time reverse transcriptase polymerase 
chain reaction (RT-PCR) was performed on collected nasal and throat swabs on days 1 
(study enrollment), 3, 6 and 10 to determine the influenza virus(sub-)type, viral load and 
resistance mutations in the neuraminidase (NA) gene (H275Y, R292K, E119V, R150K, 
D197N, N294S) [15,17]. Viral RNA loads (RNA copies [log10/ml]) were determined by 
converting the cycle threshold value to viral particle counts (viral RNA copies), by processing 
electron-microcopy-counted influenza A/Puerto Rico/8/34 and B/Lee/40 virus stocks 
(Advanced Biotechnologies Inc., Maryland, USA) in parallel to the patient samples.  
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Statistical analysis 
Data from all children enrolled during the entire 7-years of IRIS were evaluated. Patients who 
received more than one NA inhibitor treatment or other antivirals were excluded. Children 
were stratified into age groups according to presumed immunity development [6,7]: 6 
months; 6 months1 year; 13 years; 35 years; 510 years and 1013 years. 
 Continuous data, such as viral load, were summarized as means and standard 
deviations (SD), medians and ranges were calculated/reported to one decimal point. 
Categorical data were summarized as frequency and percentage of the appropriate study 
population. The area under the curve (AUC) of the virus load was determined using the 
trapezoid rule. Student’s t-test was used to compare AUC values between age groups. 
Logistic multivariable analyses were performed to explore the association between duration 
of viral RNA detection and baseline viral load, age (years), antiviral treatment, virus subtype, 
influenza virus vaccination status during the previous 4 months and emergence of resistance 
in the post-baseline samples. The dependent variable was “cleared” or “not cleared” 
depending on RNA detection on day 6. The association of emergence of resistance 
mutations with baseline viral load, age (years) and influenza virus subtype was analyzed by a 
regression analysis. Results of the regression analyses are shown as odd ratios (OR) and 
confidence intervals (CI) with significance determined by chi-squared (2) test.  
Kaplan-Meier plots for time to non-detection of viral RNA by quantitative RT-PCR and 
for time to symptom resolution were generated for various age strata using the recorded 
symptoms diary cards of children age 1 year. Data were censored at the date of the last 
available sample, if patients were lost to follow-up, if samples were inadequate or if RNA was 
still detected at the final visit. Wilcoxon and log-rank tests were used to compare outcomes 
between the age groups and influenza virus (sub-)type. 
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Results  
Patients characteristics and demographics 
A total of 2131 children, aged 13 years, tested positive for a single influenza virus (sub-
)type by RT-PCR (see Supplementary Figure 1 for study flow chart). Baseline characteristics 
stratified by age are summarized in Table 1 and Supplementary Tables 1 and 2 [6]. 
Relatively few infants (aged <1 year) were included in IRIS and were positive for influenza 
virus (N = 23). A total of 683 children were infected with A/H1N1pdm09, 825 with A/H3N2 
and 623 with influenza B virus. No infants aged 6 months1 year had influenza B virus 
infection. Gender was distributed similarly across all age groups. The majority of children 
received antivirals (61%). Pulmonary (13.4%) and cardiovascular (0.8%) comorbidities were 
relatively uncommon, as was influenza vaccination coverage in the previous 4 months 
(8.3%). 
 
Virological kinetics 
Baseline viral RNA load 
The mean viral RNA loads (RNA copies [log10/ml]) at the day of study enrollment (baseline) 
of all children infected with A/H1N1pdm09 and A/H3N2 virus were comparable, except in the 
small group of infants infected with A/H3N2 virus (Figure 1). Children aged 1013 years (6.3 
log10/ml) infected with influenza B virus had a significantly higher baseline viral load 
compared with children aged 110 years (range: 5.8-6.0 log10/ml; *0.05>P>0.01).  
 
Viral RNA clearance 
The change in viral RNA load over time relative to the baseline viral load was calculated for 
all children to determine the rate of viral RNA clearance (Table 2). In most cases, children 
aged 1013 years cleared viral RNA faster than younger children. For A/H1N1pdm09 virus, 
the higher rate of viral load reduction in older children was only significant at day 6. For 
A/H3N2 and influenza B virus, this effect remained significant until day 10 post-baseline.  
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 When corrected for the date of symptom onset, children aged 1013 years infected 
with A/H1N1pdm09 and A/H3N2 cleared virus faster than younger children if they were 
enrolled on the day that symptoms first occurred (n = 270) (Supplementary Figure 2A). 
A/H3N2 virus infected children aged 10 to 13 years showed a similar trend even if they were 
enrolled ≥3 days after symptom onset (Supplementary Figure 2D and E). At longer time 
periods between study enrollment and disease onset, the difference in viral RNA load 
reduction was no longer observed between the different age groups (Supplementary Figure 
2B–E).  
 
Total quantified viral RNA load in time 
The mean AUC of the viral load was calculated over the course of infection (Figure 2). 
A/H1N1pdm09 infected infants (aged <1 year, 37.3 log10/ml*time) and young children (aged 
15 years, 26.2 log10/ml*time) had significantly higher mean AUCs of 1.60- and 1.12-fold, 
respectively, than older children (aged >5 years, 23.3 log10/ml*time) (**0.01>P>0.001 and 
***P<0.001). The same trend was observed for influenza B virus infection with a 1.37- and 
1.04-fold larger total mean quantity of virus detected in infants (aged <6 months; 39.6 
log10/ml*time) and young children (aged 15 years, 29.5 log10/ml*time), respectively, 
compared with older children (aged >5 years, 28.4 log10/ml*time). Infants (aged <1 year, 16.2 
log10/ml*time) infected with A/H3N2 virus shed a lower amount of virus than older children 
(*0.05>P>0.01). The mean AUCs of A/H3N2 virus infected in children aged 15 years (28.3 
log10/ml*time) were 1.24-fold higher compared with older children (22.8 log10/ml*time) 
(**0.01>P>0.001 and ***P<0.001). When corrected for treatment status, these age-related 
effects on the total quantity of viral RNA load persisted (Supplementary Figure 3). 
 
Time to non-detection of viral RNA 
The median time to A/H1N1pdm09 virus RNA clearance was longest for young children 
(aged <5 years (N = 320), median range: 9.9-11.5 days) compared with older children (aged 
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>5 years (N = 363), median range: 7.2-9.0 days) (Figure 3A). Viral RNA clearance in A/H3N2 
virus infected older children (aged >5 years [N = 451], median range: 8.7-8.9 days) was 
faster compared with younger children (aged 15 years [N = 364], median range: 10.0-10.6 
days). Infants (aged 6 months1 year) cleared the A/H3N2 virus faster than all other children 
(Figure 3B). Older children infected with influenza B virus also tended to clear the virus faster 
than younger children, however, these differences were not statistically significant (Figure 
3C).  
 
Variables associated with viral RNA clearance 
Logistic regression analyses confirmed the relationship between duration of virus shedding 
and older age (OR 1.08 [CI: 1.05-1.12], P<0.0001). Additionally, vaccination (OR 1.72 [CI: 
1.22-2.43], P=0.0017) and antiviral treatment (OR 1.74 [CI: 1.43-2.12], P<0.0001) were 
associated with shorter duration of virus shedding. High baseline viral loads (OR 0.57 [CI: 
0.52-0.62], P<0.0001) and the emergence of resistance mutations (OR 0.05 [CI: 0.01-0.20], 
P<0.0001) were independently associated with longer duration of virus shedding. Infection 
with A/H3N2 (OR 0.71 [CI: 0.57-0.90], P=0.01) or influenza B virus (OR 0.78 [CI: 0.61-0.99], 
P=0.01) decreased the odds of viral RNA clearance compared with infection with 
A/H1N1pdm09 virus.  
 
Clinical symptoms 
Clinical signs were mild and complications were relatively rare. A total of 185 (8.7%) patients 
reported AEs. Of these, 117 (9.0%) received antiviral therapy and 68 (8.2%) were untreated 
(Supplementary Tables 3 and 4). The incidence of AEs was the highest for young children 
(aged <5 years). Serious AEs (SAEs) were reported in 14 (0.7%) children, of whom 10 
(0.8%) received oseltamivir treatment and 4 (0.5%) were untreated (Supplementary Tables 5 
and 6). Two children were admitted to the intensive care unit (ICU), one 5-month old infant 
and one 8-year old child. Both were treated with oseltamivir and recovered.  
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The duration of symptoms of older children infected with A/H1N1pdm09 and A/H3N2 
(aged >5 years, median range: 4-5 days) was shorter compared with younger children (aged 
<5 years, median range: 5-6 days; *0.05>P>0.01 and **0.01>P>0.001) (Supplementary 
Figure 4). This age-related difference in symptom duration was less pronounced when 
infected children were stratified according to their antiviral treatment status (Supplementary 
Figure 5 and 6). There was no significant observed difference in symptom resolution 
between the age groups of all children infected with influenza B virus (Supplementary 
Figures 46).  
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Emergence of resistance 
Neuraminidase inhibitor associated resistance mutations were detected in the NA gene of 
the post-baseline samples in 49 oseltamivir-treated children (2.3%), including 34 (1.6%) 
A/H1N1pdm09 viruses with the H274Y mutation and 15 (0.7%) A/H3N2 viruses with the 
R292K mutation (Table 3). No resistance mutations were detected in influenza B viruses. 
The emergence of resistance mutations was equally distributed over the entire 7-years of 
IRIS (Table 4). The prevalence of resistance was higher in children aged <5 years (n = 39) 
compared with children aged >5 years (n = 10) (Table 3).The children infected with viruses 
that acquired resistance mutations had a higher viral load at day 3 and/or 6 compared with 
children infected with wild-type A/H1N1pdm09 and A/H3N2 virus (Supplementary Figures 7 
and 8). This difference was not observed at day 10, since most children had cleared the 
virus.  
 
Variables associated with emergence of resistance 
Logistic regression analyses demonstrated that older age was associated with reduced odds 
of acquiring resistance mutations (OR 0.70 [CI: 0.62-0.81], P<0.0001). A high baseline viral 
load was associated with the development of resistance mutations (OR 1.50, P=0.005). 
Influenza A/H3N2 virus was less likely to become resistant compared with A/H1N1pdm09 
virus (OR 0.38, P=0.0016). 
 
Discussion 
The viral load at baseline and the rate of viral clearance both contribute to the total viral RNA 
load in patients with influenza virus infection. The presented data demonstrate that, over the 
duration of their infection, children aged 15 years shed a 1.04- to 1.24-fold higher total 
quantity of influenza virus compared with older children. This higher total viral burden in 
young children was observed in both untreated and oseltamivir-treated children’s age 
groups.  
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Similar to previous data, no age-related differences were observed in the baseline 
viral load of infected children in this study (excluding infants aged <1 year infected with 
A/H3N2 virus), indicating that baseline viral load did not have a direct effect on the high total 
quantity of virus shedding detected in the upper respiratory tract of infected young children 
[13,14]. The relatively low rate of viral RNA clearance observed in children aged 15 years 
may have led to their high viral burden and it most likely resulted from their immature 
immune response and/or the absence of prior exposure to influenza A viruses [6]. In contrast 
to the data presented here, several studies reported no difference in viral burden between 
children of different age groups [12–14,18]. However, those studies did not take the timing of 
symptom onset into account. The influenza virus load depends on the time when a sample is 
obtained in relation to disease onset [12,19]. When corrected for the date of symptom onset, 
this study showed that viral RNA shedding was in general still prolonged in young children 
compared with older children. Ultimately, this age-related viral load difference was no longer 
observed for children that were included ≥2 days after symptom onset. Therefore, by not 
correcting for the date of disease onset, previous studies may have failed to detect 
differences between age groups [12–14,18]. 
 Surprisingly, infants infected with A/H3N2 virus had a low baseline viral load and 
cleared viral RNA faster compared with older children, whereas the opposite was observed 
for A/H1N1pdm09 virus. Technical reasons for the observed low baseline viral load in these 
infants were ruled out first, since the same sampling and virological assays were used for all 
patients included in this study. Secondly, parents with sick infants tend to seek professional 
care earlier upon symptom onset compared with parents with older children [20]. This early 
sampling may have resulted in very low viral loads, since virus production has only just 
started. However, in this study, the time from symptom onset to study baseline in infants was 
either similar or higher than older children. As infants were not included during the first 5 
years of IRIS, only a small number of young children, primarily from the United States, were 
included in this study. This small sample size and the observed substantial variation in the 
detected viral loads makes it difficult to draw any solid conclusion from this group.  
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Age-related differences in the viral kinetics in children infected with influenza B virus 
were not as prominent as those observed in influenza A virus-infected children. According to 
available surveillance data to date, most influenza epidemics were dominated by influenza A 
virus infections [21,22]. Correspondingly, due to the absence of pre-existing immunity, 
influenza B virus infection might affect both young and older children equally [23].  
 Interestingly, despite the low observed vaccination coverage, in accordance with 
previous data, the present study showed that both vaccination and antiviral treatment 
reduced the duration of virus shedding [11,24,25]. In addition, antiviral treatment seemed to 
have a beneficial effect on symptom resolution. However, IRIS was a non-randomized 
clinical study that was not designed to determine the efficacy of antiviral treatment. 
Therefore, no conclusions were drawn regarding oseltamivir usage with clinical symptoms. 
Previous studies have suggested that antiviral therapy is associated with the development of 
resistance mutations [11,15,26–28]. Similarly, in this study only children infected with 
A/H1N1pdm09 and A/H3N2 who received oseltamivir treatment acquired resistance 
mutations. The prevalence of resistance in this study was highest in children younger than 5 
years and almost absent in the older ones, which may suggest that the protracted viral RNA 
shedding in young children allowed for the influenza viruses to evolve and acquire resistance 
mutations upon selective pressure of antiviral therapy. Similar to a previous study, 
emergence of resistant viruses did not affect symptom resolution in influenza A-infected 
children (data not shown) [16]. 
The emergence of resistance can also delay viral clearance [16]. This may be a 
contributing factor to prolonged shedding in young children prone to the developed antiviral 
resistance. However, when children who acquired antiviral resistance were excluded from 
the analysis, the probability of age to increase viral clearance remained the same (data not 
shown).   
Young children are at higher risk of acquiring severe influenza [1,4,29]. In this study, 
serious complications were rare, with only two ICU admissions and influenza-related 
symptoms that lasted for approximately 1 week. Since antiviral therapy was at the discretion 
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of the physician, it is not known whether the observed AEs were related to the antiviral usage 
or a reflection of the severity of influenza virus infection. 
In conclusion, this study showed that the baseline nasopharyngeal influenza virus 
loads were comparable between all age groups. However, over time, viral RNA shedding 
was protracted in young children (aged 15 years) compared with older children. This could 
explain why young children are more likely to develop antiviral resistance upon antiviral 
therapy and serve as spreaders of influenza virus in the community.  
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Figure legends  
 
Figure 1: Baseline viral RNA load of children infected with A/H1N1pdm09, A/H3N2 and 
influenza B virus.  
The mean baseline viral RNA load of children infected with A/H1N1pdm09 (A), A/H3N2 (B) 
and Influenza B virus (C) are depicted as mean ± standard deviation. Influenza B virus was 
not detected in infants aged 6 months1 year. Asterisks represents significant p-values 
(*0.05<P<0.01 and **0.01>P>0.001). Abbreviations: n, total number of patients; y, years. 
 
Figure 2: Total viral RNA load of children infected with A/H1N1pdm09, A/H3N2 and 
influenza B virus. 
The total amount of viral RNA shedding in children infected with A/H1N1pdm09, A/H3N2 and 
influenza B virus was determined by calculating the area under the curve (AUC). Influenza B 
virus was not detected in infants aged 6 months1 year. The bar graphs depict the mean ± 
standard deviation. Asterisks represent significant p-values (*0.05<P<0.01, **0.01>P>0.001, 
***P<0.001). Abbreviations: n, total number of patients; y, years. 
 
Figure 3: Kaplan-Meier plots for time to viral RNA clearance of children infected with 
H1N1pmd09, A/H3N2 and influenza B virus.   
Censored patients are illustrated as plus signs. The median time to viral RNA clearance in 
each age group is depicted next to the Kaplan-Meier plots. Influenza B virus was not 
detected in infants aged 6 months1 year. Asterisk represents significant p-values 
(*0.05<P<0.01, and **0.01>P>0.001). Abbreviation: N, total number of patients; CI, 
confidence interval. 
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Tables  
Table 1: Clinical characteristics of children with laboratory confirmed influenza at baseline 
Patients characteristics 
Age groups 
Total <6 months 6 months–1 year 1–3 years 3–5 years 5–10 years 10–13 years 
(N = 2131) (N = 12) (N = 11) (N = 369) (N = 473) (N = 936) (N = 330) 
Virus(sub-)type         
A/H1N1pdm09  683 (32.1%) 4 (33.3%) 7 (63.6%) 151 (40.9%) 158 (33.4%) 270 (28.8%) 93 (28.2%) 
A/H3N2 825 (38.7%) 6 (50.0%) 4 (36.4%) 150 (40.7%) 214 (45.2%) 335 (35.8%) 116 (35.2%) 
Influenza B  623 (29.2%) 2 (16.7%) 0 0 68 (18.4%) 101 (21.4%) 331 (35.4%) 121 (36.7%) 
Country         
France  396 (18.6%) 0 0 60 (16.3%) 88 (18.6%) 186 (19.9%) 62 (18.8%) 
Germany  41 (1.9%) 0 0 4 (1.1%) 15 (3.2%) 15 (1.6%) 7 (2.1%) 
Norway 3 (0.1%) 0 0 0 0 1 (0.2%) 2 (0.2%) 0 0 
Poland 573 (26.9%) 0 0 139 (37.7%) 169 (35.7%) 210 (22.4%) 55 (16.7%) 
United States 695 (32.6%) 12 (100%) 10 (90.9%) 88 (23.8%) 111 (23.5%) 336 (35.9%) 138 (41.8%) 
China (Hong Kong, 
(SARPCR)) 
369 (17.3%) 0 0 0 0 61 (16.5%) 76 (16.1%) 170 (18.2%) 62 (18.8%) 
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South Africa 22 (1.0%) 0 0 1 (9.1%) 6 (1.6%) 5 (1.1%) 8 (0.9%) 2 (0.6%) 
Australia 32 (1.5%) 0(0.0) 0(0.0) 11 (3.0) 8 (1.7) 9 (1.0) 4 (1.2) 
Gender        
Female 1031 (48.4%) 7 (58.3%) 5 (45.5%) 183 (49.6%) 236 (49.9%) 455 (48.6%) 145 (43.9%) 
Male 1100 (51.6%) 5 (41.7%) 6 (54.5 186 (50.4%) 237 (50.1%) 481 (51.4%) 185 (56.1%) 
Antiviral treatment        
No 831 (39.0%) 0 0 140 (37.9%) 210 (44.4%) 360 (38.5%) 121 (36.7%) 
Yes 1300 (61.0%) 12 (100%) 11 (100%) 229 (62.1%) 263 (55.6%) 576 (61.5%) 209 (63.3%) 
Febrile a        
No  827 (38.8%) 9 (75.0%) 5 (45.5%) 137 (37.1%) 165 (34.9%) 366 (39.1%) 145 (43.9%) 
Yes  1303 (61.1%) 3 (25.0%) 6 (54.5%) 232 (62.9%) 308 (65.1%) 570 (60.9%) 184 (55.8%) 
Cardiovascular disease        
No  2115 (99.2%) 12 (100%) 11 (100%) 365 (98.9%) 468 (98.9%) 931 (99.5%) 328 (99.4%) 
Yes  16 (0.8%) 0 0 4 (1.1%) 5 (1.1 5 (0.5%) 2 (0.6%) 
Pulmonary disease        
No  1846 (86.6%) 12 (100%) 10 (90.9%) 339 (91.9%) 424 (89.6%) 791 (84.5%) 270 (81.8%) 
Yes  285 (13.4%) 0 1 (9.1%) 30 (8.1%) 49 (10.4%) 145 (15.5%) 60 (18.2%) 
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Vaccinated in previous 4 months b        
No  1952 (91.6%) 12 (100%) 7 (63.6%) 333 (90.2%) 451 (95.3%) 851 (90.9%) 298 (90.3%) 
Yes  177 (8.3%) 0 4 (36.4%) 35 (9.5%) 22 (4.7%) 85 (9.1%) 31 (9.4%) 
Time from symptom onset to study 
baseline, d, mean (SD) 
1.2 (0.77) 1.6 (0.90) 1.4 (0.67) 1.1 (0.75%) 1.2 (0.94) 1.2 (0.70) 1.2 (0.68) 
Abbreviations: SARPRC, Special Administrative Region of the People's Republic of China; d, day; SD, standard deviation   
a Total N = 2130, febrile status of 1 patient was not reported.  
b Total N = 2129, vaccination status of 3 patients were not reported. 
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Table 2: Post-baseline mean viral load (RNA copies log10/ml) change from baseline 
Influenza virus 
(sub)-type 
Time post-baseline 
enrollment (day) 
Total a 
Age groups 
<6 months 6 months–1 year 1–3 years 3–5 years 5–10 years 10–13 years 
(N = 2131) (N = 4) (N = 7) (N = 151) (N = 158) (N = 270) (N = 93) 
A/H1N1pdm09 
3 650 -1.04 (1.37) -1.00 (1.52) -1.52 (1.80) -1.50 (1.70) -1.70 (1.75) -2.08 (1.74) 
6* 662 -1.35 (1.58) -3.12 (1.18) -3.36 (2.25) -3.48 (2.13) -3.93 (1.95) -4.18 (2.12) 
10 654 -3.77 (1.70) -5.74 (0.85) -5.01 (1.66) -4.85 (1.66) -5.06 (1.50) -5.07 (1.57) 
A/H3N2 
3** 789 -0.97 (2.42) -1.32 (0.92) -1.77 (1.79) -1.59 1.85) -2.11 (1.77) -2.18 (1.86) 
6*** 792 -3.49 (0.98) -4.04 (2.01) -3.11 (2.09) -3.08 2.09) -3.97 (1.85) -3.85 (2.07) 
10* 785 -3.97 (0.85) -4.04 (2.01) -5.21 (1.45) -4.82 1.69) -5.10 (1.50) -5.26 (1.46) 
Influenza Bb 
3* 601 -0.93 (0.64)  -1.05 (1.53) -1.23 (1.88) -1.31 (1.85) -1.83 (1.94) 
6** 599 -3.39 (1.07)  -3.25 (2.22) -3.52 (2.14) -3.43 (2.18) -4.25 (1.94) 
10** 592 -6.25 (0.16)  -4.87 (1.89) -5.20 (1.64) -5.08 (1.80) -5.76 (1.34) 
Data depicted are the mean viral load (RNA copies log10/ml) and in brackets the standard deviation. 
Reduction in the virus RNA loads (RNA copies log10/ml) are shown as minus values. The highest reduction in mean viral RNA load relative to baseline of 
children infected with A/H1N1pdm09 virus, A/H3N2 virus and influenza B virus are marked in bold.  
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a The total N swabs collected at each time point  
b Influenza B virus was not detected in infants aged 6 months–1 year.  
*Asterisk depicts the post-baseline sample day where the analysis of variance within the age groups was significant (*0.05<P< 0.01, **0.01>P>0.001 and 
***P<0.0001) 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz939/5574924 by U
niversity of N
ottingham
 user on 03 O
ctober 2019
 28 
 
 
Table 3: Emergence of resistance to neuraminidase inhibitors in children with laboratory 
confirmed A/H1N1pdm09 and A/H3N2 influenza virus at baseline. 
 Age groups 
Influenza (sub-)type a 
<6 months 
6 months–
1 year 
1–3 
years 
3–5 
years 
5–10 
years 
10–13 
years 
N = 10 N = 11 N = 301 N = 372 N = 605 N = 209 
A/H1N1pdm09  
2/4  
(50.0) 
2/7  
(28.6) 
15/151 
(9.9) 
9/158 
(5.7) 
6/270 
(2.2) 
0/93 
(0.0) 
A/H3N2 
0/6 
(0.0) 
0/4 
(0.0) 
5/150 
(3.3) 
6/214 
(2.8) 
4/335 
(1.2) 
0/116 
(0.0) 
Data are the fraction of resistant (%).  
a Data from children infected with influenza B are not shown, since no resistance mutations were 
detected in these patients. 
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Table 4: Emergence of resistance mutations over the IRIS years a 
IRIS year 
 Age groups 
Total <6 months 6 months–1 year 1–3 years 3–5 years 5–10 years 10–13 years 
N = 1508 N = 10 N = 11 N = 301 N = 372 N = 605 N = 209 
2009 7/700 (1.0%) 0 0 0/1 0/2 0/3 0/1 
2009/2010 1/293 (0.3%) 0 0 1/45 (2.2%) 0/56 0/131 0/61 
2010/2011 14/274 (5.1%) 0 0 9/64 (14.1%) 3/72 (4.2%) 2/97 (2.1%) 0/41 
2011/2012 5/131 (3.8%) 0 0 1/23 (4.4%) 2/39 (5.1%) 2/53 (3.8%) 0/16 
2012/2013 15/400 (3.8%) 0 0 6/94 (6.4%) 7/113 (6.2%) 2/144 (1.4%) 0/49 
2013/2014 7/151 (4.7%) 2/4 (50%) 2/8 (25%) 0/30 2/40 (5.0%) 1/62 (1.6%) 0/7 
2014/2015 7/252 (2.8%) 0/6 0/3 3/44 (6.8%) 1/50 (2.0%) 3/155 (2.6%) 0/34 
All years combined 49/1508 (3.3%) 2/10 (20%) 2/11 (18.2%) 20/301 (6.6%) 15/372 (4.0%) 10/605 (1.7%) 0/209 
a Data are the fraction of resistant (%), unless specified otherwise. Children infected with influenza B are excluded, since no resistance mutations were 
detected in these patients. The denominator for percentages is the total number of A/H1N1pdm09 and A/H3N2 patients by age group enrolled in the 
respective years. Children <1 year of age were not recruited during years 1 to 5 of IRIS.  
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Figure 1 
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Figure 2 
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Figure 3 
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